Company says prostate cancer vaccine shows promise

Apr 14, 2009

(AP) -- The maker of an experimental treatment for prostate cancer says the vaccine has met a key goal in a late-stage study.

Seattle-based Dendreon Corp. said Tuesday that its Provenge vaccine improved overall survival when compared to a dummy treatment in a study of 512 men. The treatment is the first to use the body's immune system.

The study has been closely watched. Advisers to the Food and Drug Administration had previously recommended approval of the vaccine. But the FDA asked for more data. That sparked protests from men's groups and cancer advocates.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: FDA approves AbbVie combo hepatitis C treatment

add to favorites email to friend print save as pdf

Related Stories

Prostate cancer vaccines more effective with hormone therapy

Jul 10, 2008

Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, ...

Cancer vaccine may be possibility

Feb 24, 2006

Researchers at the University of Washington and the Fred Hutchinson Cancer Center are working on a vaccine to prevent cancer.

Breakthrough vaccine to treat chemo-resistant ovarian cancer

Mar 08, 2007

Cancer Treatment Centers of America announced today its plans to launch a new cancer vaccine therapy that expands treatment options for thousands of women with advanced stage ovarian cancer. This innovative treatment will ...

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

1 hour ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.